Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors
- PMID: 21147910
- PMCID: PMC3012925
- DOI: 10.1101/gr.107961.110
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors
Abstract
Advanced prostate cancer can progress to systemic metastatic tumors, which are generally androgen insensitive and ultimately lethal. Here, we report a comprehensive genomic survey for somatic events in systemic metastatic prostate tumors using both high-resolution copy number analysis and targeted mutational survey of 3508 exons from 577 cancer-related genes using next generation sequencing. Focal homozygous deletions were detected at 8p22, 10q23.31, 13q13.1, 13q14.11, and 13q14.12. Key genes mapping within these deleted regions include PTEN, BRCA2, C13ORF15, and SIAH3. Focal high-level amplifications were detected at 5p13.2-p12, 14q21.1, 7q22.1, and Xq12. Key amplified genes mapping within these regions include SKP2, FOXA1, and AR. Furthermore, targeted mutational analysis of normal-tumor pairs has identified somatic mutations in genes known to be associated with prostate cancer including AR and TP53, but has also revealed novel somatic point mutations in genes including MTOR, BRCA2, ARHGEF12, and CHD5. Finally, in one patient where multiple independent metastatic tumors were available, we show common and divergent somatic alterations that occur at both the copy number and point mutation level, supporting a model for a common clonal progenitor with metastatic tumor-specific divergence. Our study represents a deep genomic analysis of advanced metastatic prostate tumors and has revealed candidate somatic alterations, possibly contributing to lethal prostate cancer.
Figures


References
-
- Agell L, Hernandez S, de Muga S, Lorente JA, Juanpere N, Esgueva R, Serrano S, Gelabert A, Lloreta J 2008. KLF6 and TP53 mutations are a rare event in prostate cancer: Distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol 21: 1470–1478 - PubMed
-
- Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA 2007. CHD5 is a tumor suppressor at human 1p36. Cell 128: 459–475 - PubMed
-
- Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ 1996. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86: 263–274 - PubMed
-
- Dong JT 2006. Prevalent mutations in prostate cancer. J Cell Biochem 97: 433–447 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous